AMTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Amentum Holdings Inc (AMTM) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows some positive financial growth trends, the technical indicators and trading sentiment do not strongly support an immediate buy decision. Additionally, hedge funds are selling, and there are no significant positive catalysts or trading signals to justify immediate action.
The MACD is below 0 and negatively contracting, suggesting bearish momentum. RSI is neutral at 41.719, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 30.616, with resistance at 31.793 and support at 29.439. Overall, the technical indicators suggest a neutral to slightly bearish outlook.
Analysts have raised price targets recently, with BTIG and Cantor Fitzgerald highlighting the company's expansion into high-growth areas like Space Systems and Global Nuclear Energy.
Financial performance shows a significant increase in net income (+266.67% YoY) and EPS (+260.00% YoY), indicating improved profitability.
Hedge funds are selling heavily, with a 3056.33% increase in selling activity over the last quarter.
Revenue dropped by 5.24% YoY in Q1 2026, reflecting potential challenges in growth.
No recent congress trading data or significant insider activity to support confidence in the stock.
The company's Q1 2026 financials show mixed results. Revenue declined by 5.24% YoY to $3.237 billion, but net income increased by 266.67% YoY to $44 million, and EPS rose by 260% YoY to 0.18. Gross margin also improved slightly to 7.17%. While profitability is improving, the revenue decline raises concerns about growth sustainability.
Analysts have raised price targets recently, with BofA setting a target of $30 (Neutral), BTIG raising it to $35 (Buy), and Cantor Fitzgerald increasing it to $40 (Overweight). Analysts highlight the company's potential in high-growth areas and improved margins but note uncertainties in civilian agency funding and conservative guidance.
